MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients-Reference-Cited by-同舟云学术

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients

Published:2009-02 Issue:2 Volume:20 Page:298-304
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cappuzzo F.,Jänne P.A.,Skokan M.,Finocchiaro G.,Rossi E.,Ligorio C.,Zucali P.A.,Terracciano L.,Toschi L.,Roncalli M.,Destro A.,Incarbone M.,Alloisio M.,Santoro A.,Varella-Garcia M.

Funder

Italian Association for Cancer Research to FC

US National Institute of Health

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/20/2/298/394239/mdn635.pdf

Reference35 articles.

1. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

2. Erlotinib in lung cancer molecular and clinical predictors of outcome;Tsao;N Engl J Med,2005

3. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer;Hirsch;J Clin Oncol,2006

4. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer;Cappuzzo;J Natl Cancer Inst,2005

5. Prospective study of gefitinib in EGFR FISH positive/P-Akt positive or never smoker patients with advanced non-small cell lung cancer (NSCLC): the ONCOBELL trial;Cappuzzo;J Clin Oncol,2007

Cited by 275 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

2. Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study;Biomedicines;2024-06-25

3. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non–Small Cell Lung Cancer;JCO Precision Oncology;2024-05

4. TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer;Oncogene;2024-03-01

5. The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC;JTO Clinical and Research Reports;2024-02